Using Daratumumab in the Front Line for Multiple Myeloma
Posted: Oct 22, 2020
Using Daratumumab in the Front Line for Multiple Myeloma image

Daratumumab could make its way to newly diagnosed myeloma patients, based on results from the second part of the Phase III CASSIOPEIA study. This is a study that includes 1085 newly diagnosed, transplant eligible patients using daratumumab as induction with bortezomib, thalidomide and dex (VTd) or VTd alone with a second study part using daratumumab as maintenance vs. no treatment. 

In the first part of the study, patients were randomized to receive induction and consolidation treatment with daratumumab combined with bortezomib, thalidomide and dexamethasone (VTd) or VTd alone. The primary endpoint was the number of patients that achieved a stringent complete response (sCR). Patients then went on to stem cell transplant and used the Dara-VTd or VTd as consolidation therapy following transplant. 

In the second part of the study, patients that achieved a response underwent a second randomization to either receive maintenance treatment of daratumumab 16 mg/kg every 8 weeks for up to 2 years versus no further treatment (observation). The primary endpoint of this part of the study is progression free survival.

The second part of this study was conducted by the French Intergroupe Francophone du Myelome (IFM), the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen.

The study showed improved progression free survival and a 47% reduction in the risk of progression or death in patients treated with daratumumab. No new safety concerns were identified. Based on the results, Janssen plans to submit data on the subject at upcoming hematology meetings. 

We hope to learn more details as the American Society of Hematology meeting approaches in December and look forward to finding more effective up-front treatments for newly diagnosed patients. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811